IND clearance for Fibrogen’s Gal9-targeting monoclonal antibody for solid tumors
June 4, 2024
Fibrogen Inc. has received IND clearance from the FDA allowing the company to initiate a phase I trial of FG-3165, a galectin-9 (Gal9)-targeted monoclonal antibody under development for treatment of solid tumors characterized by high levels of Gal9 expression.